Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

The week-ending August 8 saw 20 companies in the healthcare sector report their quarterly earnings. With the earnings season ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Adjusted earnings per share (EPS) of $2.01 beat the Zacks Consensus Estimate of $1.95 and remained flat year over year.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Dow Jones Top Company Headlines at 9 PM ET: Intel's CEO, Under Attack From Trump, Is Already at Odds With His Board | Expedia ... Intel's CEO, Under Attack From Trump, Is Already at Odds With His ...

Dow Jones Top Company Headlines at 7 PM ET: Trump Calls on Intel CEO to Resign Over China Ties | Expedia ... The president appeared to be referencing Lip-Bu Tan's past business dealings in China, ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and Livdelzi.